NSE Circulars (2977)
National Stock Exchange of India circulars including trading guidelines, compliance requirements, market operations updates, and regulatory changes affecting market participants.
| Date | Circular | Tags | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NSE introduces 3 securities under Enhanced Surveillance Measure (ESM) Stage I with 100% margin requirement and trade-for-trade settlement … | |||||||||||||||
NSE introduces 3 securities under Enhanced Surveillance Measure (ESM) Stage I with 100% margin requirement and trade-for-trade settlement effective November 24, 2025.
| |||||||||||||||
NSE implements Short-Term Additional Surveillance Measure (ST-ASM) on 8 securities with increased margin requirements of 50% or existing … | |||||||||||||||
NSE implements Short-Term Additional Surveillance Measure (ST-ASM) on 8 securities with increased margin requirements of 50% or existing margin (whichever is higher) effective November 24, 2025.
| |||||||||||||||
NSE updates block trading parameters with minimum order size increased to Rs. 25 Crores and price range expanded to ±3%, effective December … | |||||||||||||||
NSE updates block trading parameters with minimum order size increased to Rs. 25 Crores and price range expanded to ±3%, effective December 08, 2025.
| |||||||||||||||
SMS Lifesciences India Limited will be renamed to HALEOS LABS LIMITED with symbol change from SMSLIFE to HALEOSLABS effective November 26, … | |||||||||||||||
SMS Lifesciences India Limited will be renamed to HALEOS LABS LIMITED with symbol change from SMSLIFE to HALEOSLABS effective November 26, 2025.
| |||||||||||||||
Invesco Mutual Fund is changing the nomenclature of plans in select schemes from November 21, 2025, renaming investor plans to 'Regular … | |||||||||||||||
Invesco Mutual Fund is changing the nomenclature of plans in select schemes from November 21, 2025, renaming investor plans to 'Regular Plan' and 'Direct Plan' for schemes launched prior to December 31, 2012.
| |||||||||||||||
Axis Mutual Fund's Multi-Asset Active Fund of Funds NFO will be available for subscription on NSE MF Invest Platform from November 21 to … | |||||||||||||||
Axis Mutual Fund's Multi-Asset Active Fund of Funds NFO will be available for subscription on NSE MF Invest Platform from November 21 to December 05, 2025.
| |||||||||||||||
Mahindra Manulife Income Plus Arbitrage Active FOF NFO will be available for transactions on NSE MF Invest Platform from November 21, 2025 … | |||||||||||||||
Mahindra Manulife Income Plus Arbitrage Active FOF NFO will be available for transactions on NSE MF Invest Platform from November 21, 2025 to December 01, 2025, with six plan options across Regular and Direct categories.
| |||||||||||||||
Beta Drugs Limited's equity shares listed on NSE Capital Market Segment (Main Board) following migration from SME Emerge platform, effective … | |||||||||||||||
Beta Drugs Limited's equity shares listed on NSE Capital Market Segment (Main Board) following migration from SME Emerge platform, effective November 13, 2025.
| |||||||||||||||
Beta Drugs Limited's equity shares are being listed on the NSE Main Board following migration from the SME Emerge platform, with … | |||||||||||||||
Beta Drugs Limited's equity shares are being listed on the NSE Main Board following migration from the SME Emerge platform, with shareholding pattern as of November 13, 2025.
| |||||||||||||||
NSE notifies listing of 79,311,773 equity shares of Capillary Technologies India Limited on Capital Market segment effective November 21, … | |||||||||||||||
NSE notifies listing of 79,311,773 equity shares of Capillary Technologies India Limited on Capital Market segment effective November 21, 2025 at issue price of Rs. 577 per share.
| |||||||||||||||